# Deltex Medical Group plc Publication of Annual Report and Notification of AGM

- Link: https://www.directorstalkinterviews.com/deltex-medical-group-plc-publication-annual-report-notification-agm/412751259
- Published: 2018-05-17T07:13:16+01:00
- Author: Giles Arbor

**Deltex Medical Group plc** (LON:DEMG), the global leader in Oesophageal Doppler
Monitoring, today gives notice that its Annual Report and Accounts for the year 
ended 31 December 2017 has been published on the “Annual & Interim Reports” section
of the Company’s website at www.deltexmedical.com.

The Company announced a summary of its results on 9 May 2018 and expects to post
printed copies of the Annual Report & Accounts 2017 on 23 May 2018 to shareholders
who have informed the Company of their wish to receive reports of this nature in
hard copy.

Deltex also announces that its Annual General Meeting will be held at 11:00am on
20 June 2017 at the offices of DAC Beachcroft LLP, 100 Fetter Lane, London EC4A 
1BN. The formal notice and resolutions can be found at the back of the Annual Report&
Accounts 2017. The related proxy card is expected to be posted on 23 May 2018 to
shareholders on the register on 11 May 2018.

Deltex Medical Group Plc manufactures and markets haemodynamic monitoring technologies.
Deltex Medical’s proprietary ODM (TrueVueTM Doppler) is the only technology to measure
blood flow in the central circulation in real time. Minimally invasive, easy to 
set up and quick to focus, the technology generates a low-frequency ultrasound signal,
which is highly sensitive to changes in flow and measures them immediately. Deltex
has been the only Group in the enhanced haemodynamic space to build a robust and
credible evidence base proving the clinical and economic benefits of its core technology,
TrueVueTM Doppler which is proven to reduce complications suffered by patients after
surgery and save hospitals the costs of treating those complications.

Deltex Medical’s TrueVueTM System on the CardioQ-ODM+ monitor platform also now 
provides clinicians with two further advanced haemodynamic monitoring technologies.
High Definition Impedance Cardiography is an entirely non-invasive monitoring technology
which creates an electrical field across the chest and measures the disruption to
this field when the heart pumps blood. Pulse Pressure Waveform Analysis uses peripheral
blood pressure signal analysis to give doctors information on changes in the circulation
and is particularly suited to monitoring lower risk or haemodynamically stable patients.

**Group goal**

Haemodynamic management is now becoming widely accepted as an important major new
medical modality. Consequently, the Group’s focus is on maximising value from the
opportunities presented as enhanced haemodynamic management is adopted into routine
clinical practice around the world. The Group aims to provide clinicians with a 
single platform, a ‘haemodynamic workstation’, which offers them a range of technologies
from simple to sophisticated to be deployed according to the patient’s condition
and skill and expertise of the user. Doing this will enable the Group to partner
healthcare providers to support modern haemodynamic management across the whole 
hospital.

Share on:
